Comparison of a novel antigen detection test with reverse transcription polymerase chain reaction assay for laboratory diagnosis of SARS-CoV-2 infection.
COVID-19
Nasopharyngeal swab samples
RT-PCR
Rapid antigen test
SARS-CoV-2
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
27
01
2022
accepted:
07
04
2022
pubmed:
6
5
2022
medline:
31
1
2023
entrez:
5
5
2022
Statut:
ppublish
Résumé
Molecular diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by real-time reverse transcription polymerase chain reaction (RT-PCR) in respiratory specimens is considered the gold standard method. This method is highly sensitive and specific but it has some limitations such as being expensive and requiring special laboratory equipment and skilled personnel. RapidFor™ Antigen Rapid Test Kit is a commercially available Ag-RDT which is produced in Turkey and designed to detect the nucleocapsid antigen of SARS-CoV-2 in nasopharyngeal swab samples. The aim of this study was to evaluate the performance of this novel SARS-CoV-2 antigen detection considering the RT-PCR method as the gold standard. Four hundred forty-four nasopharyngeal swab samples which were collected from the patients who met clinical criteria of COVID-19 from ten centers in Turkey between September 2020 and February 2021 were included in the study. All the nasopharyngeal swab samples were tested for SARS-CoV-2 RNA using commercial RT-PCR kits (Bioeksen and A1 Lifesciences, İstanbul, Turkey) according to the manufacturer's instructions. Viral loads were assessed according to the cycle threshold (Ct) values. RapidFor™ SARS-CoV-2 antigen test (Vitrosens Biotechnology, Istanbul, Turkey) was used to investigate the presence of SARS-CoV-2 antigen in all samples following the manufacturer's instructions. Out of 444 nasopharyngeal swab samples tested, 346 (77.9%) were positive and 98 (22.1%) were negative for SARS-CoV-2 RNA by RTPCR. Overall sensitivity of the RapidFor™. Antigen Rapid Test Kit was 80.3% whereas specificity was found to be 87.8%. Positivity rate of rapid antigen test in samples with Ct values over 25 and below 30 was 82.7%, while it increased to 95.7% in samples 20 ≤ Ct < 25 and reached 100% in samples with Ct values below 20. RapidFor™ SARS-CoV-2 Ag test might be a good choice in the screening of symptomatic and asymptomatic patients and their contacts for taking isolation measures early, with advantages over RT-PCR as being rapid, easy and being applicable in every laboratory and even at point of care.
Identifiants
pubmed: 35513690
doi: 10.1007/s15010-022-01832-9
pii: 10.1007/s15010-022-01832-9
pmc: PMC9070611
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-96Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045 .
doi: 10.2807/1560-7917.ES.2020.25.3.2000045
OMS, Laboratory Testing Strategy Recommendations for COVID-19. Interim Guidance, 21 march 2020.
Scohy A, Anantharajah A, Bodeus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. J Clin Virol. 2020;129: 104455.
doi: 10.1016/j.jcv.2020.104455
Blairon L, Wilmet A, Beukinga I, Tre-Hardy M. Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: experiences of a general hospital. J Clin Virol. 2020;129: 104472.
doi: 10.1016/j.jcv.2020.104472
Chaimayo C, Kaewnaphan B, Tanlieng N, Athipanyasilp N, Sirijatuphat R, Chayakulkeeree M, Angkasekwinai N, Sutthent R, Puangpunngam N, Tharmviboonsri T, Pongraweewan O, Chuthapisith S, Sirivatanauksorn Y, Kantakamalakul W, Horthongkham N. Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand. Virol J. 2020;17:177.
doi: 10.1186/s12985-020-01452-5
Perez-Garcia F, Romanyk J, Moya Gutierrez H, Labrador Ballestero A, Perez Ranz I, Gonzalez Arroyo J, Gonzalez Ventosa V, Perez-Tanoira R, Domingo Cruz C, Cuadros-Gonzalez J. Comparative evaluation of Panbio and SD biosensor antigen rapid diagnostic tests for COVID-19 diagnosis. J Med Virol. 2021;93:5650–4.
doi: 10.1002/jmv.27089
Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, Chan RC, Tsang DN. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. J Clin Virol. 2020;129: 104500.
doi: 10.1016/j.jcv.2020.104500
Perez-Garcia F, Perez-Tanoira R, Romanyk J, Arroyo T, Gomez-Herruz P, Cuadros-Gonzalez J. Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: a prospective single-center study. J Clin Virol. 2020;129: 104473.
doi: 10.1016/j.jcv.2020.104473
Aoki K, Nagasawa T, Ishii Y, Yagi S, Kashiwagi K, Miyazaki T, Tateda K. Evaluation of clinical utility of novel coronavirus antigen detection reagent, Espline(R) SARS-CoV-2. J Infect Chemother. 2021;27:319–22.
doi: 10.1016/j.jiac.2020.11.015
Ishii T, Sasaki M, Yamada K, Kato D, Osuka H, Aoki K, Morita T, Ishii Y, Tateda K. Immunochromatography and chemiluminescent enzyme immunoassay for COVID-19 diagnosis. J Infect Chemother. 2021;27:915–8.
doi: 10.1016/j.jiac.2021.02.025
Ristic M, Nikolic N, Cabarkapa V, Turkulov V, Petrovic V. Validation of the STANDARD Q COVID-19 antigen test in Vojvodina Serbia. PLoS ONE. 2021;16: e0247606.
doi: 10.1371/journal.pone.0247606
Linares M, Perez-Tanoira R, Carrero A, Romanyk J, Perez-Garcia F, Gomez-Herruz P, Arroyo T, Cuadros J. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. J Clin Virol. 2020;133: 104659.
doi: 10.1016/j.jcv.2020.104659
Yamayoshi S, Sakai-Tagawa Y, Koga M, Akasaka O, Nakachi I, Koh H, Maeda K, Adachi E, Saito M, Nagai H, Ikeuchi K, Ogura T, Baba R, Fujita K, Fukui T, Ito F, Hattori SI, Yamamoto K, Nakamoto T, Furusawa Y, Yasuhara A, Ujie M, Yamada S, Ito M, Mitsuya H, Omagari N, Yotsuyanagi H, Iwatsuki-Horimoto K, Imai M, Kawaoka Y. Comparison of rapid antigen tests for COVID-19. Viruses. 2020;12:1420.
doi: 10.3390/v12121420
Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernandez-Fuentes MA, Martinez M, Poujois S, Forque L, Valdivia A, Solano de la Asuncion C, Ferrer J, Colomina J, Navarro D. Field evaluation of a rapid antigen test (Panbio COVID-19 Ag rapid test device) for COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect. 2021;27:e7–10.
doi: 10.1016/j.cmi.2020.11.004
Candel FJ, Barreiro P, San Roman J, Abanades JC, Barba R, Barberan J, Bibiano C, Canora J, Canton R, Calvo C, Carretero M, Cava F, Delgado R, Garcia-Rodriguez J, Gonzalez Del Castillo J, Gonzalez de Villaumbrosia C, Hernandez M, Losa JE, Martinez-Peromingo FJ, Molero JM, Munoz P, Onecha E, Onoda M, Rodriguez J, Sanchez-Celaya M, Serra JA, Zapatero A. Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings. Rev Esp Quimioter. 2020;33:466–84.
doi: 10.37201/req/120.2020
European comission. Commission recommendation of 18.11.2020 on the use of rapid antigen tests for the diagnosis of SARS‐CoV‐2 infection. https://ec.europa.eu/health/sites/health/files/preparedness_response/docs/sarscov2_rapidantigentests_recommendation_en.pdf . Accessed 8 Nov 2020.
European Centre for Disease Prevention and Control. Options for the use of rapid antigen tests for COVID‐19 in the EU/EEA and the UK. TECHNICAL REPORT. https://www.ecdc.europa.eu/en/publications-data/options-use-rapid-antigentests-covid-19-eueea-and-uk . Accessed 28 Oct 2020.
Marks M, Millat-Martinez P, Ouchi D, Roberts CH, Alemany A, Corbacho-Monne M, Ubals M, Tobias A, Tebe C, Ballana E, Bassat Q, Baro B, VallMayans M, G Beiras C, Prat N, Ara J, Clotet B, Mitja O. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021;21:629–36.
doi: 10.1016/S1473-3099(20)30985-3
Weiss A, Jellingso M, Sommer MOA. Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: a systematic review and meta-analysis. EBioMedicine. 2020;58: 102916.
doi: 10.1016/j.ebiom.2020.102916
Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, Taylor J, Spicer K, Bardossy AC, Oakley LP, Tanwar S, Dyal JW, Harney J, Chisty Z, Bell JM, Methner M, Paul P, Carlson CM, McLaughlin HP, Thornburg N, Tong S, Tamin A, Tao Y, Uehara A, Harcourt J, Clark S, Brostrom-Smith C, Page LC, Kay M, Lewis J, Montgomery P, Stone ND, Clark TA, Honein MA, Duchin JS, Jernigan JA, Public H-S, King C, Team CC-I. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med. 2020;382:2081–90.
doi: 10.1056/NEJMoa2008457
Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, Emperador D, Takwoingi Y, Cunningham J, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Taylor-Phillips S, Hooft L, Leeflang MM, Spijker R, Van den Bruel A, Cochrane C-DTAG. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2020;8:013705.
La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020;39:1059–61. https://doi.org/10.1007/s10096-020-03913-9 .
doi: 10.1007/s10096-020-03913-9
Anika S, Monika P, Andre C, Jamie LB, Vanessa S, Joanna E, Shamez L, Maria Z, Robin G. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19. Euro Surveill. 2020. https://doi.org/10.2807/1560-7917.ES.2020.25.32.2001483 .
doi: 10.2807/1560-7917.ES.2020.25.32.2001483
Kretschmer A, Kossow A, Grüne B, Schildgen O, Mathes T, Schildgen V. False positive rapid antigen tests for SARS-CoV-2 in the real-world and their economic burden. J Infect. 2022;84:248–88. https://doi.org/10.1016/j.jinf.2021.08.020 (Epub 2021 Aug 17).
doi: 10.1016/j.jinf.2021.08.020
World Health Organization. Antigen‐detection in the diagnosis of SARS‐ CoV‐2 infection using rapid immunoassays. https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov2infection-using-rapid-immunoassays . Accessed 11 Sept 2020.